We are live on ! Find out more
AHL

Abel Hall LLC Portfolio holdings

AUM $579M
1-Year Est. Return 54.21%
This Fund
S&P 500
This Quarter Est. Return
+26.06%
1 Year Est. Return
+54.21%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$579M
AUM Growth
+$109M
Cap. Flow
+$34.2M
Cap. Flow %
5.91%
Top 10 Hldgs %
25.32%
Holding
1,093
New
282
Increased
378
Reduced
228
Closed
138

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$2.57M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$2.05M
3
DFAC icon
Dimensional US Core Equity 2 ETF
DFAC
+$1.51M
4
LLY icon
Eli Lilly
LLY
+$1.28M
5
BHF icon
Brighthouse Financial
BHF
+$958K

Top Sells

Rank Stock Value
1
TM icon
Toyota
TM
+$1.03M
2
APA icon
APA Corp
APA
+$1.01M
3
MRK icon
Merck
MRK
+$950K
4
T icon
AT&T
T
+$808K
5
WDS icon
Woodside Energy
WDS
+$777K

Sector Composition

Rank Sector Weight
1 Technology 19.99%
2 Financials 9.6%
3 Healthcare 8.6%
4 Industrials 8.26%
5 Consumer Discretionary 5.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
851
LENZ Therapeutics
LENZ
$184M
$90.2K 0.02%
+15,876
New +$128K
ABUS icon
852
Arbutus Biopharma
ABUS
$871M
$87.8K 0.02%
18,300
-1,773
-9% -$7.79K
TRON
853
Tron Inc
TRON
$745M
$87.7K 0.02%
+54,473
New +$110K
AKBA icon
854
Akebia Therapeutics
AKBA
$341M
$86K 0.01%
+75,438
New +$89.8K
SPRY icon
855
ARS Pharmaceuticals
SPRY
$563M
$84.4K 0.01%
+10,536
New +$90.6K
BTBT icon
856
Bit Digital
BTBT
$459M
$83.8K 0.01%
46,551
+16,385
+54% +$28.8K
SABA
857
Saba Capital Income & Opportunities Fund II
SABA
$221M
$83.5K 0.01%
10,000
– –
TDUP icon
858
ThredUp
TDUP
$760M
$82.2K 0.01%
11,997
+179
+2% +$837
OPRT icon
859
Oportun Financial
OPRT
$264M
$81.6K 0.01%
14,290
+1,935
+16% +$10.4K
OEC icon
860
Orion
OEC
$400M
$79.3K 0.01%
11,962
-361
-3% -$2.6K
CATX icon
861
Perspective Therapeutics
CATX
$327M
$78.4K 0.01%
22,994
+11,200
+95% +$42.3K
ZURA icon
862
Zura Bio
ZURA
$526M
$78.1K 0.01%
13,229
+40
+0.3% +$191
OPEN icon
863
Opendoor
OPEN
$3.8B
$77.7K 0.01%
16,828
+6,031
+56% +$28.9K
HNST icon
864
The Honest Company
HNST
$421M
$77.7K 0.01%
21,225
+280
+1% +$944
KRO icon
865
KRONOS Worldwide
KRO
$712M
$77.7K 0.01%
12,267
+70
+0.6% +$480
EVH icon
866
Evolent Health
EVH
$421M
$76.7K 0.01%
+14,150
New +$54.3K
OVID icon
867
Ovid Therapeutics
OVID
$440M
$76.2K 0.01%
28,324
-2,865
-9% -$7.39K
NG icon
868
NovaGold Resources
NG
$2.55B
$75.8K 0.01%
12,693
+9
+0.1% +$75
MRVI icon
869
Maravai LifeSciences
MRVI
$1.01B
$75.5K 0.01%
12,097
-811
-6% -$3.5K
UAA icon
870
Under Armour
UAA
$3.04B
$75K 0.01%
+11,735
New +$69.5K
SATL icon
871
Satellogic
SATL
$523M
$73.3K 0.01%
12,812
+123
+1% +$900
TROX icon
872
Tronox
TROX
$981M
$73.1K 0.01%
11,602
-817
-7% -$6.93K
RC
873
Ready Capital
RC
$261M
$71.3K 0.01%
+40,733
New +$71.6K
ACH
874
Accendra Health
ACH
$249M
$68.8K 0.01%
20,113
+601
+3% +$1.87K
ACTG icon
875
Acacia Research
ACTG
$447M
$67.2K 0.01%
14,416
-36
-0.2% -$173
33 34
35
36 37

Similar funds

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
WCCM
Webs Creek Capital Management Dallas, Texas $578M AUM 79.84% 1-Year Est. Return
MIOT
Massachusetts Institute of Technology Cambridge, Massachusetts $577M AUM 8.5% 1-Year Est. Return
AF
Aegis Financial Mc Lean, Virginia $580M AUM 105.74% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $581M AUM 46.16% 1-Year Est. Return
EIP
Ellis Investment Partners Berwyn, Pennsylvania $576M AUM 16.04% 1-Year Est. Return
SCM
Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return
TCM
Trybe Capital Management Greenwich, Connecticut $581M AUM 112.96% 1-Year Est. Return

Abel Hall LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Abel Hall LLC held 1,093 positions worth $579M, up 23% from $469M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Abel Hall LLC deployed $34.2M of net new capital in Q2 2026, opening 282 new positions and adding to 378 existing holdings. Its largest new stake was Brighthouse Financial: 15,398 shares worth $975K.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Merck, an estimated $950K trimmed.

  • Abel Hall LLC's largest Q2 2026 buy was Brighthouse Financial: 15,398 shares worth $975K.
  • Abel Hall LLC added most to Microsoft in Q2 2026, an estimated $2.57M increase.
  • Abel Hall LLC's biggest Q2 2026 reduction was Merck, cutting an estimated $950K.
  • Abel Hall LLC fully exited Toyota in Q2 2026, selling an estimated $1.03M.
  • Abel Hall LLC's ten largest holdings make up 25% of its $579M portfolio in Q2 2026.
  • Abel Hall LLC opened 282 new positions and closed 138 in Q2 2026.
  • Abel Hall LLC's portfolio value rose 23% quarter-over-quarter to $579M.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.